Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism

被引:189
作者
Deakin, S
Leviev, I
Gomaraschi, M
Calabresi, L
Franceschini, G
James, RW
机构
[1] Univ Hosp Geneva, Div Endocrinol & Diabetol, Clin Diabet Unit, CH-1211 Geneva 14, Switzerland
[2] Univ Milan, Dept Pharmacol Sci, Ctr E Grossi Paoletti, I-20133 Milan, Italy
关键词
D O I
10.1074/jbc.M107440200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Paraoxonase-1 (PON1) is a high density lipoprotein (HDL)-associated serum enzyme that protects low density lipoproteins from oxidative modifications. There is a relative lack of information on mechanisms implicated in PON1 release from cells. The present study focused on a model derived from stable transfection of CHO cells, to avoid co-secretion of apolipoprotein (apo) A-I and lipids, which could lead to formation of HDL-like complexes. Our results indicate that, in the absence of an appropriate acceptor, little PON1 is released. The results designate HDL as the predominant, physiological acceptor, whose efficiency is influenced by size and composition. Neither lipid-poor apoA-I or apoA-II nor low density lipoproteins could substitute for HDL. Protein-free phospholipid complexes promoted PON1 release. However, the presence of both apolipoprotein and phospholipid were necessary to promote release and stabilize the enzyme. Immunofluorescence studies demonstrated that PON1 was inserted into the external membrane of CHO cells, where it was enzymatically active. Accumulation of PON1 in the cell membrane was not influenced by the ability of the cell to co-secrete of apoA-1. Release appeared to involve desorption by HDL; human and reconstituted HDL promoted PON1 release in a saturable, high affinity manner (apparent affinity 1.59 +/- 0.3 mug of HDL protein/ml). Studies with PON1-transfected hepatocytes (HuH-7) revealed comparable structural features with the peptide located in a punctate pattern at the external membrane and enzymatically active. We hypothesize that release of PON1 involves a docking process whereby HDL transiently associate with the cell membrane and remove the peptide from the external membrane. The secretory process may be of importance for assuring the correct lipoprotein destination of PON1 and thus its functional efficiency.
引用
收藏
页码:4301 / 4308
页数:8
相关论文
共 38 条
[1]   SERUM PARAOXONASE ACTIVITY, CONCENTRATION, AND PHENOTYPE DISTRIBUTION IN DIABETES-MELLITUS AND ITS RELATIONSHIP TO SERUM-LIPIDS AND LIPOPROTEINS [J].
ABBOTT, CA ;
MACKNESS, MI ;
KUMAR, S ;
BOULTON, AJ ;
DURRINGTON, PN .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (11) :1812-1818
[2]   The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns [J].
Antikainen, M ;
Murtomaki, S ;
Syvanne, M ;
Pahlman, R ;
Tahvanainen, E ;
Jauhiainen, M ;
Frick, MH ;
Ehnholm, C .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (04) :883-885
[3]   Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions - A possible peroxidative role for paraoxonase [J].
Aviram, M ;
Rosenblat, M ;
Bisgaier, CL ;
Newton, RS ;
Primo-Parmo, SL ;
La Du, BN .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (08) :1581-1590
[4]  
BAGDADE JD, 1989, J LAB CLIN MED, V113, P235
[5]   IDENTIFICATION OF A DISTINCT HUMAN HIGH-DENSITY-LIPOPROTEIN SUBSPECIES DEFINED BY A LIPOPROTEIN-ASSOCIATED PROTEIN, K-45 - IDENTITY OF K-45 WITH PARAOXONASE [J].
BLATTER, MC ;
JAMES, RW ;
MESSMER, S ;
BARJA, F ;
POMETTA, D .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1993, 211 (03) :871-879
[6]   Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation [J].
Boemi, M ;
Leviev, I ;
Sirolla, C ;
Pieri, C ;
Marra, M ;
James, RW .
ATHEROSCLEROSIS, 2001, 155 (01) :229-235
[7]   Reconstituted high-density lipoproteins with a disulfide-linked apolipoprotein A-I dimer: Evidence for restricted particle size heterogeneity [J].
Calabresi, L ;
Vecchio, G ;
Frigerio, F ;
Vavassori, L ;
Sirtori, CR ;
Franceschini, G .
BIOCHEMISTRY, 1997, 36 (41) :12428-12433
[8]   The paraoxonase Leu-Met54 and Gln-Arg191 gene polymorphisms are not associated with the risk of coronary heart disease [J].
Gardemann, A ;
Philipp, M ;
Hess, K ;
Katz, N ;
Tillmanns, H ;
Haberbosch, W .
ATHEROSCLEROSIS, 2000, 152 (02) :421-431
[9]  
Garin M.C., 1997, J CLIN INVEST, V99, P62
[10]   QUANTIFICATION OF HUMAN SERUM PARAOXONASE BY ENZYME-LINKED IMMUNOASSAY - POPULATION DIFFERENCES IN PROTEIN CONCENTRATIONS [J].
GARIN, MCB ;
ABBOTT, C ;
MESSMER, S ;
MACKNESS, M ;
DURRINGTON, P ;
POMETTA, D ;
JAMES, RW .
BIOCHEMICAL JOURNAL, 1994, 304 :549-554